A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
evaluate the clinical efficacy and safety of azacitidine combined with HAG regimen for
patients with int/high -risk MDS and AML-MRC with less than 30% blasts compared with
azacitidine